CAJ | 학술논문

目的探讨芪苈强心胶囊对矽肺患者N-末端脑钠肽前体(NT-proBNP)水平和心功能的影响.方法对住院矽肺患者中有心力衰竭患者按自愿原则分成治疗组(41例)和对照组(30例),两组均进行综合对症治疗,治疗组在此基础上加用芪苈强心胶囊,总疗程6个月.观察治疗前后NT-proBNP测定值,6min步行试验,超声心动图、NYHA心功能分级.结果 NYHA心功能分级评估显示,治疗组有效率为29.27％,对照组有效率为10.00％,两组有效率的差异有统计学意义(P＜0.05).治疗组治疗前平均步行距离(150.96±73.12)m,治疗后平均步行距离(169.32±77.04)m,治疗前后平均步行距离的差异有统计学意义(P＜0.05).治疗组治疗前平均NT-proBNP(1154.44±480.79) ng/L,治疗后为(494.49±342.61)ng/L,治疗前后NT-proBNP的差异有统计学意义(P＜0.01).治疗组治疗前后左室射血分数(LVEF)的差异有统计学意义(P＜0.05).结论在综合治疗基础上,加用芪苈强心胶囊可以明显降低矽肺患者的NT-proBNP水平,增强矽肺患者心功能.
목적 탐토기력강심효낭대석폐환자N-말단뇌납태전체(NT-proBNP)수평화심공능적영향.방법 대주원석폐환자중유심력쇠갈환자안자원원칙분성치료조(41례)화대조조(30례),량조균진행종합대증치료,치료조재차기출상가용기력강심효낭,총료정6개월.관찰치료전후NT-proBNP측정치,6min보행시험,초성심동도、NYHA심공능분급.결과 NYHA심공능분급평고현시,치료조유효솔위29.27％,대조조유효솔위10.00％,량조유효솔적차이유통계학의의(P＜0.05).치료조치료전평균보행거리(150.96±73.12)m,치료후평균보행거리(169.32±77.04)m,치료전후평균보행거리적차이유통계학의의(P＜0.05).치료조치료전평균NT-proBNP(1154.44±480.79) ng/L,치료후위(494.49±342.61)ng/L,치료전후NT-proBNP적차이유통계학의의(P＜0.01).치료조치료전후좌실사혈분수(LVEF)적차이유통계학의의(P＜0.05).결론 재종합치료기출상,가용기력강심효낭가이명현강저석폐환자적NT-proBNP수평,증강석폐환자심공능.
Objective To investigate the effects of Qili Qiangxin capsules on the amino-terminal probrain natriuretic peptide (NT-proBNP) level and cardiac function in patients with silicosis.Methods Hospitalized silicosis patients with heart failure were divided into treatment group (41 cases) and control group (30 cases) according to their own will.Both groups received comprehensive symptomatic treatment; in addition,the treatment group received Qili Qiangxin capsules.The treatment lasted 6 months.The observed items included NT-proBNP level,5-minute walk test,ultrasonic cardiogram,and NYHA classification before and after treatment.Results According to NYHA classification,the response rate was 29.27％ in the treatment group and 10.00％ in the control group; there was a significant difference between the two groups (P＜0.05).The average walk distance in the treatment group was increased from 150.96±73.12 m before treatment to 169.32±77.04 m after treatment,and the improvement was statistically significant (P＜0.05).The average NT-proBNP level in the treatment group was reduced from 1154.44 ±480.79 ng/L before treatment to 494.49 ±342.61 ng/L after treatment,and the reduction was statistically significant (P＜0.01).Left ventricular ejection fraction was significantly improved in the treatment group (P＜0.05).Conclusion Qili Qiangxin capsules in addition to comprehensive symptomatic treatment can significantly reduce NT-proBNP level and improve cardiac function in silicosis patients,and thereby improve patients' quality of life.